bearish
Sipai Health Technology (314.HK) - Unjustified Valuation and Problematic Business Model
289 Views29 Mar 2023 09:15
The sustainability/stability of Sipai’s performance/growth potential is worrying. Weak profitability make Sipai hard to be breakeven.High valuation is hard to sustain due to problematic business model
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- MedSci Healthcare Holdings (2415.HK) - Lack of Control over Core Resources Is a Critical Pain Point28 Sep 2023
- Sipai Health Technology (314.HK) - Valuation Has Collapsed, but a Reversal Is Not yet in Sight27 Sep 2023
- CanSino Biologics (6185.HK) 2022 Results - It Is Time to Reassess CanSino and Its Future Prospects29 Mar 2023
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
x